Small Molecule West Nile Virus Inhibitors

小分子西尼罗河病毒抑制剂

基本信息

  • 批准号:
    7404500
  • 负责人:
  • 金额:
    $ 20.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-03 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Due to its high prevalence and its ability to cause severe disease in humans for which treatments are unavailable, West Nile (WN) virus has become an important public health concern in the U.S. The unmet medical need of developing effective WN virus therapeutics has been recognized by NIAID, which includes several flaviviruses in its current list of category A-C pathogens. The long-term objective of this project is to develop a small molecule therapeutic to treat severe West Nile (WN) virus infections in humans. The specific goal of this study is to identify small molecule inhibitors of WN virus by high throughput screening (HTS) and select among them lead compounds for future drug development. To this end, we have developed an in vitro WN virus infection assay using wild type virus and a human cell line. This assay was adapted to high-throughput format and was used to screen a small library of compounds from which three previously unknown WN virus inhibitors were identified. The Phase I project will expand this repertoire by screening additional compound libraries. `Screening hits' will then be critically evaluated for potency, selectivity, cytotoxicity and `druggability' in order to select lead candidates for detailed drug characterizations in Phase II studies. Successful development of a small molecule therapeutic for WN virus infections should provide the basis for similar therapeutics to treat other flavivirus infections of wider global importance, such as dengue fever. West Nile (WN) virus causes severe illness in the elderly and people with compromised immune systems. The virus is transmitted by mosquitoes and is widespread in the USA. There is no proven treatment available. This research will identify small molecule drugs to treat illness caused by WN virus infections in humans.
描述(由申请人提供):由于西尼罗河病毒(WN)的高流行率和其在人类中引起严重疾病的能力,且无法获得治疗,因此西尼罗河病毒(WN)已成为美国重要的公共卫生问题。NIAID已认识到开发有效的WN病毒治疗方法的医疗需求未得到满足,其中包括几种黄病毒在其目前的A-C类病原体清单中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KAREN G. ANTHONY其他文献

KAREN G. ANTHONY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KAREN G. ANTHONY', 18)}}的其他基金

Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy
用于类风湿关节炎治疗的变构 MIF 抑制剂
  • 批准号:
    9381096
  • 财政年份:
    2016
  • 资助金额:
    $ 20.1万
  • 项目类别:
Therapeutic Inhibition of MIF in Rheumatoid Arthritis
MIF 在类风湿性关节炎中的治疗抑制作用
  • 批准号:
    8252707
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
针对 D-丙氨酸途径的广谱抗菌药物
  • 批准号:
    8501252
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Therapeutic Inhibition of MIF in Rheumatoid Arthritis
MIF 在类风湿性关节炎中的治疗抑制作用
  • 批准号:
    7670901
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
针对 D-丙氨酸途径的广谱抗菌药物
  • 批准号:
    8109403
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
针对 D-丙氨酸途径的广谱抗菌药物
  • 批准号:
    8288773
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
针对 D-丙氨酸途径的广谱抗菌药物
  • 批准号:
    8034385
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
针对 D-丙氨酸途径的广谱抗菌药物
  • 批准号:
    7644650
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Therapeutic Inhibition of MIF in Rheumatoid Arthritis
MIF 在类风湿性关节炎中的治疗抑制作用
  • 批准号:
    8546227
  • 财政年份:
    2009
  • 资助金额:
    $ 20.1万
  • 项目类别:
Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis
小分子丙氨酸消旋酶抑制剂作为结核病的新疗法
  • 批准号:
    7159222
  • 财政年份:
    2006
  • 资助金额:
    $ 20.1万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 20.1万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 20.1万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 20.1万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 20.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了